The worldwide market for biopharmaceuticals and the number of new pro tein drugs are rapidly increasing. For every new drug a new purification process must be developed. For some drugs this can be achieved by modify ing the process parameters used in an existing process whereas for other drugs a whole new process must be developed. This can be a challenging and very costly process, which in the worst case delays the product launch. The problem can be largely overcome by implementing affinity chromatography. However, there is a need for affinity ligands for purifying non-immunoglob ulins. We present here an overview of technologies and suppliers within the field of development of affinity chromatography media.